Moncef Slaoui - 22 Jun 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
23 Jun 2026, 16:30:00 UTC
Prior SEC filing
23 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Moncef Slaoui, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Moncef Slaoui filed Form 4 for Vaxcyte, Inc. (PCVX) on 23 Jun 2026.

Key facts

  • This page summarizes Moncef Slaoui's Form 4 filing for Vaxcyte, Inc. (PCVX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 23 Jun 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 23 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712369 Primary reporting owner

Slaoui Moncef

Relationship
Director
Address
C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS
Signature
Moncef Slaoui, by /s/ Peter N. Efremenko, Attorney-In-Fact
Signature date
23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+26,061
Change %
Price
$0.000000*
Shares after
26,061
Date
22 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
26,061
Exercise price
$52.11
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .